Ponesimod
Brand names: Ponvory · Active ingredient: Ponesimod
In short: PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
What is Ponesimod used for?
PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Ponesimod dosage
Before initiation of treatment with PONVORY, assess the following:
Complete Blood Count
Obtain a recent (i.e., within the last 6 months or after discontinuation of prior MS therapy) complete blood count (CBC), including lymphocyte count
.
Cardiac Evaluation
Obtain an electrocardiogram (ECG) to determine whether preexisting conduction abnormalities are present. In patients with certain preexisting conditions, advice from a cardiologist should be sought and first-dose monitoring is recommended
.
Determine whether patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction
.
Liver Function Tests
Obtain recent (i.e., within the last 6 months) transaminase and bilirubin levels
.
Ophthalmic Evaluation
Obtain an evaluation of the fundus, including the macula
.
Current or Prior Medications with Immune System Effects
If patients are taking anti-neoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with PONVORY
.
Vaccinations
Test patients for antibodies to varicella zoster virus (VZV) before initiating PONVORY; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with PONVORY
. If live
attenuatedvaccine immunizations are required, administer at least 1 month prior to initiation of PONVORY.
Maintenance Dosage
After dose titration is complete
, the recommended maintenance dosage of PONVORY is 20 mg taken orally once daily starting on Day 15.
Administer PONVORY orally once daily. Swallow the tablet whole. PONVORY can be taken with or without food.
Treatment Initiation
A starter pack must be used for patients initiating treatment with PONVORY
. Initiate PONVORY treatment with a 14-day titration; start with one 2 mg tablet orally once daily and progress with the titration schedule as shown in Table 1
.
Titration Day | Daily Dose
Days 1 and 2 | 2 mg
Days 3 and 4 | 3 mg
Days 5 and 6 | 4 mg
Day 7 | 5 mg
Day 8 | 6 mg
Day 9 | 7 mg
Day 10 | 8 mg
Day 11 | 9 mg
Days 12, 13, and 14 | 10 mg
Maintenance | Daily Dose
Day 15 and thereafter | 20 mg
If dose titration is interrupted, missed dose instructions must be followed
.
Because initiation of PONVORY treatment results in a decrease in heart rate (HR), first-dose 4-hour monitoring is recommended for patients with sinus bradycardia [HR less than 55 beats per minute (bpm)], first- or second-degree [Mobitz type I] AV block, or a history of myocardial infarction or heart failure occurring more than 6 months prior to treatment initiation and in stable condition
. …
How to take Ponesimod — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Administration
Tell patients not to discontinue PONVORY without first discussing this with the prescribing healthcare provider. Advise patients to contact their healthcare provider if they accidently take more PONVORY than prescribed.
Instruct patients to administer tablets whole.
Risk of Infections
Inform patients that they may have an increased risk of infections, some of which could be life-threatening, when taking PONVORY and for 1 to 2 weeks after stopping it, and that they should contact their healthcare provider if they develop symptoms of infection
. Advise patients that the use of some vaccines containing live virus (live
attenuatedvaccines) should be avoided during treatment with PONVORY, and PONVORY should be paused 1 to 2 weeks prior and until 4 weeks after a planned vaccination. Recommend that patients postpone treatment with PONVORY for at least 1 month after VZV vaccination. Inform patients that prior or concomitant use of drugs that suppress the immune system may increase the risk of infection. …
Warnings & precautions
Do not take this medicine if: PONVORY is contraindicated in patients who:
In the last 6 months, have experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure
Have presence of Mobitz type II second-degree, third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless patient has a functioning pacemaker
Risk of Infections
PONVORY causes a dose-dependent reduction in peripheral lymphocyte count to 30–40% of baseline values because of reversible sequestration of lymphocytes in lymphoid tissues
. PONVORY may therefore increase the susceptibility to infections. Life-threatening and rare fatal infections have been reported in association with other sphingosine 1-phosphate (S1P) receptor modulators.
In Study 1
, the overall rate of infections was comparable between the PONVORY-treated patients and those receiving teriflunomide 14 mg (54.2% vs 52.1%, respectively). PONVORY increased the risk of upper respiratory tract infections. Serious or severe infections occurred in 1.6% of PONVORY-treated patients compared to 0.9% of patients receiving teriflunomide 14 mg.
Before initiating treatment with PONVORY, results from a recent (i.e., within 6 months or after discontinuation of prior therapy) complete blood count including lymphocyte count should be reviewed.
Initiation of treatment with PONVORY should be delayed in patients with active infection until resolution. Lymphocyte counts returned to the normal range in 90% of patients within 1 week of stopping therapy in modeling studies
. In Study 1, peripheral lymphocyte counts returned to normal range within 2 weeks after discontinuation of PONVORY, which was the first timepoint evaluated. …
Ponesimod side effects
The following serious adverse reactions are described elsewhere in labeling:
Infections
Bradyarrhythmia and Atrioventricular Conduction Delays
Respiratory Effects
Liver Injury
Increased Blood Pressure
Cutaneous Malignancies
Fetal Risk
Macular Edema
Posterior Reversible Encephalopathy Syndrome
Unintended Additive Immunosuppressive Effects From Prior Treatment With Immunosuppressive or Immune-Modulating Therapies
Severe Increase in Disability After Stopping PONVORY
Immune System Effects After Stopping PONVORY
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 1438 MS patients have received PONVORY at doses of at least 2 mg daily. These patients were included in Study 1 (2-year active-controlled versus teriflunomide 14 mg)
and in a Phase 2 (6-month placebo-controlled) study in patients with MS and the uncontrolled extension studies.
In Study 1, 82% of PONVORY-treated patients completed 2 years of study treatment, compared to 82.2% of patients receiving teriflunomide 14 mg. Adverse events led to discontinuation of treatment in 8.7% of PONVORY-treated patients, compared to 6% of patients receiving teriflunomide 14 mg. …
Drug interactions
PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration
.
When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system
.
Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended.
PONVORY can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.
PONVORY has not been studied in patients taking QT prolonging drugs.
Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) anti-arrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia. If treatment with PONVORY is considered, advice from a cardiologist should be sought. …
About this medicine
PONVORY (ponesimod) is a sphingosine 1-phosphate receptor modulator.
The chemical name for ponesimod is (2
Z,5
Z)-5-[3-chloro-4-[(2
R)-2,3-dihydroxypropoxy]benzylidene]-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one. It has one chiral center with absolute configuration of
(R). Its molecular formula is C
23H
25ClN
2O
4S and its molecular weight is 460.97 g/mol. Ponesimod has the following structural formula:
Ponesimod is a white to light yellowish powder that is practically insoluble or insoluble in water.
PONVORY
®(ponesimod) is provided as 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and 20 mg film-coated tablets for oral administration.
Each tablet contains the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone K30, silica colloidal anhydrous, and sodium lauryl sulfate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5be69660-738c-4db7-b0d4-517aa873dc41. Read the full official label on DailyMed.